How research paved the way for a revolution in pancreatic cancer care

While medical advances have led to improvements in survival rates for those receiving treatment for breast cancer, colon cancer and more, pancreatic cancer has remained a stubborn challenge for oncologists. However, a recent study on a new treatment for pancreatic cancer has oncologists and patients alike feeling optimistic and excited.

Hematologist oncologist William Jeffrey Edenfield, MD, has been following the research on daraxonrasib, and spoke with us on how this new treatment went from an idea to being prescribed to patients throughout the world.

The basics: K-Ras proteins and the “always on” problem

“To understand how the new pancreatic cancer treatment works, we need to break down just how pancreatic cancer develops,” said Dr. Edenfield. “Understanding that begins with the K-Ras protein.”

Most cancers have a variety of causes, including environmental, genetic and more. Nearly all pancreatic tumors, on the other hand, are driven by spontaneous mutation in a gene called KRAS, which makes the K-Ras protein.

The K-Ras protein is designed to drive cellular growth when active, which is its normal function. When the cancer-causing mutation happens, it essentially takes that function and makes it “always on.”

Imagine a faucet where it’s stuck always pouring water. Only the bathtub is already full, and the water is beginning to flood the rest of the house.

Chemotherapy, which inhibits cell growth, doesn’t “turn off” the faucet and, when it comes to pancreatic cancer specifically, is a little more like pressing your hand under the faucet to staunch the water. It may help, but the root cause remains.

Targeting K-Ras proteins to flip the ‘off’ switch

“The dream of targeting the RAS family of proteins isn’t new. In fact, it’s decades old,” said Dr. Edenfield. “Small molecule inhibitors have had success in treating other forms of cancer caused by genetic mutations, and there have been ongoing attempts to use these kinds of treatments for pancreatic cancer, too.”

While there were some successes, Dr. Edenfield noted that in the end, it just wasn’t effective at targeting the “always on” version of the protein.

The K-Ras protein is unique in another way, too. While small molecule inhibitors usually work by ‘binding’ themselves to small, pitted areas along the surface of the protein, K-Ras doesn’t have those pitted areas. Inhibitors simply slid along the smooth surface and couldn’t bind to it.

For a long time, researchers and oncologists despaired that K-Ras was “undruggable.” Then daroxonrasib started to show serious promise.

The results of research into daroxonrasib led to a standing ovation for a reason

“Phase I trials for daroxonrasib began in 2022, mainly focused on finding the right dosage and looking into whether or not there would be problems with toxicity,” said Dr. Edenfield. “Remarkably, there was a lot of promise and activity shown even early on during the trials.”

RASolute 302, the Phase III trial recently completed on 500 patients with advanced pancreatic cancer, involved participants who almost entirely had the specific gene mutation associated with pancreatic cancer. All the selected trial participants had still seen cancer growth during standard chemotherapy. Patients were randomly assigned either daraxonrasib or chemotherapy at a nearly 50/50 rate.

The researchers’ startling, incredible conclusion? Patients who received daraxonrasib had a median survival of 13.2 months, while those who received chemotherapy had a 6.7 month median survival rate. Even better, treatment-related adverse events that led to having to discontinue the treatment, such as intense or severe nausea, numbness or pain, occurred in just 1.2% of patients treated with daraxonrasib, while 11.2% of those on chemotherapy had to stop treatment.

“This represented a doubling of survival with this new targeted agent,” said Dr. Edenfield. “We really can’t overstate how exciting this is for treating pancreatic cancer moving forward.”

The results of the RASolute 302 trial were announced during the 2026 American Society of Clinical Oncology meeting in Chicago, Illinois, by Dr. Brian M. Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute. In a deeply unusual result, not only did Dr. Wolpin’s announcement make national and international news, he also received a standing ovation from the room full of physicians, researchers and more.

Daraxonrasib may set the stage for treating other stubborn cancers, too

“RAS mutations are found in many cancers, notably colon cancer, lung cancer and melanoma,” said Dr. Edenfield. “There may be hope in the future for similar treatment options targeted at those specific mutations.”

Currently, daraxonrasib is FDA-approved and available for oncologists to prescribe as part of treatment for advanced pancreatic cancer. Clinical trials are ongoing for the use of daraxonrasib alongside chemotherapy, before surgery, after surgery or even as a preventive medication for those who have a high risk of developing pancreatic cancer.

“Other K-Ras inhibitor medications are in development now as well,” said Dr. Edenfield. “While daraxonrasib isn’t a cure, it’s still potentially a game changer when it comes to treating cancers caused by RAS mutations.”